湖北医药学院学报2025，Vol.44Issue(6)：696-702,7.DOI:10.13819/j.issn.2096-708X.2025.06.008
维奈克拉联合阿扎胞苷与预激方案(HAG)治疗老年急性髓系白血病的临床疗效比较
Treatment of Elderly Patients with Acute Myeloid Leukemia by Venetoclax Combined with Azacitidine and the Priming Regimen(HAG):A Clinical Comparison
摘要
Abstract
Objective To compare the clinical efficacy and safety of Venetoclax combined with Azacitidine(VEN+AZA)versus the priming regimen(HAG)for treating acute myeloid leukemia(AML)in elderly patients aged over 60 years who are ineligible for intensive chemotherapy.Methods A retrospective analysis was conducted on 52 AML patients admitted to Shanghai Fengxian District Central Hospital from January 2021 to December 2024.Patients were divided into the VEN+AZA group(29 cases)and the HAG group(23 cases).Adverse effects,response rate,minimal residual disease(MRD)level,and survival outcomes were evaluated in both groups.Prognostic factors were analyzed by Cox regression models,and sur-vival curves for overall survival(OS)and disease-free survival(DFS)were explored using the Kaplan-Meier method.Re-sults The CR/CRi rate for the VEN+AZA group after two courses of treatment was 75.9%(22/29),higher than 39·1%(9/23)in the HAG group(P＜0.05).The negative MRD rate was 58.6%in the VEN+AZA group and 30.4%in the HAG group(P＜0.05).The VEN+AZA group had median time to neutrophil recovery of 10.0 d(9.5,12.0),shorter than 14.0 d(13.0,16.0)in the HAG group(P＜0.001).The number of red blood cell transfusions(P＜0.001)and platelet transfu-sions(P=0.025)required in the VEN+AZA group was less than in the HAG group.During a median follow-up of 24 months,the median OS had not yet been reached in the VEN+AZA group,while it was 10.5 months in the HAG group(P=0.004).Multivariate analysis indicated that the VEN+AZA regimen was an independent prognostic factor for OS(HR=0·285,95%CI=0.122-0.668).Conclusion The VEN+AZA regimen significantly improves the remission rate,MRD neg-ativity,and OS in elderly AML patients compared with the HAG regimen,and it demonstrates a favorable safety profile.关键词
急性髓系白血病/老年/维奈克拉/预激方案Key words
Acute myeloid leukemia/Elderly/Venetoclax/Priming regimen引用本文复制引用
SONG Lei-na,WANG Su-li,LIN Cai-qin,SHI Hui-zhen,LING Hui-jun,ZHU Bin,PAN Shao-ying,DING Zhi-yong,ZHAO Wen-li..维奈克拉联合阿扎胞苷与预激方案(HAG)治疗老年急性髓系白血病的临床疗效比较[J].湖北医药学院学报,2025,44(6):696-702,7.基金项目
上海市奉贤区血液病临床诊疗中心建设项目(fxlczlzx-a-202105) （fxlczlzx-a-202105）
